a randomized crossover study between glargine U 300 and degludec in patients with type 1 diabetes

a randomized crossover study between glargine U 300 and degludec in patients with type 1 diabetes - a randomized crossover study between glargine U 300 and degludec in patients with type 1 diabetes

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019525

Enrollment

Registered

2015-10-29

Start date

2015-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 1 diabetes

Interventions

insulin glargine U 300 injection once daily for two months insulin degludec injection once daily for two months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: # diabetes duration >2 years # multiple daily injection therapy # long acting insulin injection once a day # HbA1c under 9%

Exclusion criteria

Exclusion criteria: # pregnant # oral steroid therapy # advanced diabetes coomplication

Design outcomes

Primary

Measure	Time frame
the degree of rising blood glucose value over 24 hours from insulin injection	—

Secondary

Measure	Time frame
frequency of hypoglycemia and insulin dose	—

Countries

Japan

Contacts

Public ContactHirose Masakazu

Osaka City University Pediatrics

hirose810@med.osaka-cu.ac.jp06-6645-3816

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026